Logo image of CHA

CHAGEE HOLDINGS LTD-ADR (CHA) Stock Fundamental Analysis

NASDAQ:CHA - Nasdaq - US15743P1049 - ADR - Currency: USD

21.24  -0.87 (-3.93%)

Premarket: 21.28 +0.04 (+0.19%)

Fundamental Rating

4

CHA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. No worries on liquidiy or solvency for CHA as it has an excellent financial health rating, but there are worries on the profitability. CHA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CHA was profitable.
CHA had a positive operating cash flow in the past year.
CHA Yearly Net Income VS EBIT VS OCF VS FCFCHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1B 2B

1.2 Ratios

Industry RankSector Rank
ROA 36.15%
ROE 66.45%
ROIC 54.54%
ROA(3y)7.97%
ROA(5y)N/A
ROE(3y)-66.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHA Yearly ROA, ROE, ROICCHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Industry RankSector Rank
OM 23.27%
PM (TTM) 19.22%
GM 49.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHA Yearly Profit, Operating, Gross MarginsCHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 20 -20 40

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CHA is creating value.
The number of shares outstanding for CHA remains at a similar level compared to 1 year ago.
CHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CHA Yearly Shares OutstandingCHA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
CHA Yearly Total Debt VS Total AssetsCHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2B 4B 6B

2.2 Solvency

CHA has an Altman-Z score of 10.16. This indicates that CHA is financially healthy and has little risk of bankruptcy at the moment.
CHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.16
ROIC/WACC6.27
WACC8.7%
CHA Yearly LT Debt VS Equity VS FCFCHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 1B 2B 3B

2.3 Liquidity

CHA has a Current Ratio of 2.37. This indicates that CHA is financially healthy and has no problem in meeting its short term obligations.
CHA has a Quick Ratio of 2.31. This indicates that CHA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.31
CHA Yearly Current Assets VS Current LiabilitesCHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 228.63% over the past year.
CHA shows a strong growth in Revenue. In the last year, the Revenue has grown by 167.35%.
EPS 1Y (TTM)228.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)167.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 133.84% on average over the next years. This is a very strong growth
CHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 141.69% yearly.
EPS Next Y789.41%
EPS Next 2Y227.73%
EPS Next 3Y133.84%
EPS Next 5YN/A
Revenue Next Year797%
Revenue Next 2Y235.85%
Revenue Next 3Y141.69%
Revenue Next 5YN/A

3.3 Evolution

CHA Yearly Revenue VS EstimatesCHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
CHA Yearly EPS VS EstimatesCHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 5 10 15 20

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.54, the valuation of CHA can be described as very reasonable.
The average S&P500 Price/Earnings ratio is at 26.82. CHA is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.01 indicates a reasonable valuation of CHA.
The average S&P500 Price/Forward Earnings ratio is at 36.21. CHA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.54
Fwd PE 8.01
CHA Price Earnings VS Forward Price EarningsCHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF 10.96
EV/EBITDA 7.97
CHA Per share dataCHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

CHA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CHA's earnings are expected to grow with 133.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y227.73%
EPS Next 3Y133.84%

More info and screens

0

5. Dividend

5.1 Amount

CHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHAGEE HOLDINGS LTD-ADR

NASDAQ:CHA (8/1/2025, 8:00:00 PM)

Premarket: 21.28 +0.04 (+0.19%)

21.24

-0.87 (-3.93%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.21%
Inst Owner Change72032100%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.95B
Analysts82.5
Price Target41.62 (95.95%)
Short Float %1.73%
Short Ratio1.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.22%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.3%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 11.54
Fwd PE 8.01
P/S 2.29
P/FCF 10.96
P/OCF 10.03
P/B 7.93
P/tB 7.98
EV/EBITDA 7.97
EPS(TTM)1.84
EY8.66%
EPS(NY)2.65
Fwd EY12.48%
FCF(TTM)1.94
FCFY9.13%
OCF(TTM)2.12
OCFY9.97%
SpS9.26
BVpS2.68
TBVpS2.66
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 36.15%
ROE 66.45%
ROCE 67.16%
ROIC 54.54%
ROICexc N/A
ROICexgc N/A
OM 23.27%
PM (TTM) 19.22%
GM 49.57%
FCFM 20.93%
ROA(3y)7.97%
ROA(5y)N/A
ROE(3y)-66.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover1.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 396.13%
Cap/Sales 1.94%
Interest Coverage 250
Cash Conversion 96.27%
Profit Quality 108.9%
Current Ratio 2.37
Quick Ratio 2.31
Altman-Z 10.16
F-Score9
WACC8.7%
ROIC/WACC6.27
Cap/Depr(3y)307.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)228.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y789.41%
EPS Next 2Y227.73%
EPS Next 3Y133.84%
EPS Next 5YN/A
Revenue 1Y (TTM)167.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year797%
Revenue Next 2Y235.85%
Revenue Next 3Y141.69%
Revenue Next 5YN/A
EBIT growth 1Y168.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.75%
OCF growth 3YN/A
OCF growth 5YN/A